Biovaxys Technology Corp (BVAXF)

$0.10 +0.01 (7.19%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 21,500
Avg Vol 49,762
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 52%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
wheresdannynow
wheresdannynow Feb. 20 at 8:22 PM
$KRYS is crushing it with Vyjuvek sales and pipeline wins. That’s what biotech patience looks like when it pays. While big caps like $LLY $NVO stay crowded, small caps can reprice hard when data lines up. $BIOV.CSE $BVAXF quietly stacking positive DPX data in ovarian, bladder, and breast cancer. Platform stories heat up fast once momentum builds. Biotech does not reward panic. It rewards positioning.
0 · Reply
Ventureville
Ventureville Feb. 20 at 3:57 PM
Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.
0 · Reply
the_goat1
the_goat1 Feb. 20 at 1:38 PM
$BVAXF has cleared structural hurdles and continues advancing its DPX platform. Still early, but each step builds a stronger foundation for upcoming trials and potential partnerships.
0 · Reply
Ventureville
Ventureville Feb. 19 at 5:59 PM
$BIOV.CSE $BVAXF is sitting in the uncomfortable zone where biotech bottoms are usually formed.
1 · Reply
Ventureville
Ventureville Feb. 18 at 6:26 PM
$BIOV.CSE $BVAXF quietly putting up real data. Latest ovarian cancer update from the PESCO trial showing durable immune response + strong disease control with MVP-S combo. Not hype, actual clinical progress. Microcap with platform upside.
2 · Reply
Ventureville
Ventureville Feb. 13 at 2:33 PM
Decent week close for $BIOV.CSE $BVAXF. More positive trial updates rolled in January on bladder and ovarian, and collabs are moving. DPX still has legs for the longer haul.
0 · Reply
Golden_Cross
Golden_Cross Feb. 12 at 3:38 PM
$BVAXF SpayVac Breakthrough: Single-dose immunocontraceptive slashed deer fertility to 11% (vs. 86% control) in peer-reviewed study—validated across 3 species. Regulatory submissions underway for horses/deer; royalties expected early 2026!
0 · Reply
wheresdannynow
wheresdannynow Feb. 11 at 10:52 PM
Nice one, BioVaxys getting invited back to CEPI for more DPX talks next month. Platform looks promising for pandemic prep stuff. Keeping an eye on this! $BVAXF $BIOV.CSE
0 · Reply
Golden_Cross
Golden_Cross Feb. 11 at 10:45 PM
$BVAXF Many Reasons To Like BioVaxys Here! ~ Portfolio of over 120 patents acquired from IMV Inc. ~ World-Wide Investor Exposure. Traded on 3 Markets: (OTCQB: BVAXF) (CSE: BIOV) (FSE: 5LB) ~ Strong leadership ~ Collaborations with McMaster, Sona Nanotech, Merck, NIH, and more ~ Strong Drug Pipeline ~ Near-Term Revenue Producing (should see in next qtr. filing) ~ Licensees: SpayVac for Wildlife, Inc.and Zoetis ~ Ongoing Clinical Studies ~ Collaborations and Licensing for the DPX™platform ~ Debt cleanup via share settlements ~ Great Share Structure: 44m O/S ~ Market Cap Only $5.2 million
0 · Reply
Ventureville
Ventureville Feb. 11 at 2:59 PM
Feels like a paid ad, but honestly it’s not bad for anyone who wants a quick primer on $BVAXF $BIOV.CSE https://www.youtube.com/shorts/e1JL3T9sOlY If you’re new and need the basics on the pipeline and positioning, it’s a decent starting point. Just don’t confuse promotion with due diligence.
1 · Reply
Latest News on BVAXF
No data available.
wheresdannynow
wheresdannynow Feb. 20 at 8:22 PM
$KRYS is crushing it with Vyjuvek sales and pipeline wins. That’s what biotech patience looks like when it pays. While big caps like $LLY $NVO stay crowded, small caps can reprice hard when data lines up. $BIOV.CSE $BVAXF quietly stacking positive DPX data in ovarian, bladder, and breast cancer. Platform stories heat up fast once momentum builds. Biotech does not reward panic. It rewards positioning.
0 · Reply
Ventureville
Ventureville Feb. 20 at 3:57 PM
Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.
0 · Reply
the_goat1
the_goat1 Feb. 20 at 1:38 PM
$BVAXF has cleared structural hurdles and continues advancing its DPX platform. Still early, but each step builds a stronger foundation for upcoming trials and potential partnerships.
0 · Reply
Ventureville
Ventureville Feb. 19 at 5:59 PM
$BIOV.CSE $BVAXF is sitting in the uncomfortable zone where biotech bottoms are usually formed.
1 · Reply
Ventureville
Ventureville Feb. 18 at 6:26 PM
$BIOV.CSE $BVAXF quietly putting up real data. Latest ovarian cancer update from the PESCO trial showing durable immune response + strong disease control with MVP-S combo. Not hype, actual clinical progress. Microcap with platform upside.
2 · Reply
Ventureville
Ventureville Feb. 13 at 2:33 PM
Decent week close for $BIOV.CSE $BVAXF. More positive trial updates rolled in January on bladder and ovarian, and collabs are moving. DPX still has legs for the longer haul.
0 · Reply
Golden_Cross
Golden_Cross Feb. 12 at 3:38 PM
$BVAXF SpayVac Breakthrough: Single-dose immunocontraceptive slashed deer fertility to 11% (vs. 86% control) in peer-reviewed study—validated across 3 species. Regulatory submissions underway for horses/deer; royalties expected early 2026!
0 · Reply
wheresdannynow
wheresdannynow Feb. 11 at 10:52 PM
Nice one, BioVaxys getting invited back to CEPI for more DPX talks next month. Platform looks promising for pandemic prep stuff. Keeping an eye on this! $BVAXF $BIOV.CSE
0 · Reply
Golden_Cross
Golden_Cross Feb. 11 at 10:45 PM
$BVAXF Many Reasons To Like BioVaxys Here! ~ Portfolio of over 120 patents acquired from IMV Inc. ~ World-Wide Investor Exposure. Traded on 3 Markets: (OTCQB: BVAXF) (CSE: BIOV) (FSE: 5LB) ~ Strong leadership ~ Collaborations with McMaster, Sona Nanotech, Merck, NIH, and more ~ Strong Drug Pipeline ~ Near-Term Revenue Producing (should see in next qtr. filing) ~ Licensees: SpayVac for Wildlife, Inc.and Zoetis ~ Ongoing Clinical Studies ~ Collaborations and Licensing for the DPX™platform ~ Debt cleanup via share settlements ~ Great Share Structure: 44m O/S ~ Market Cap Only $5.2 million
0 · Reply
Ventureville
Ventureville Feb. 11 at 2:59 PM
Feels like a paid ad, but honestly it’s not bad for anyone who wants a quick primer on $BVAXF $BIOV.CSE https://www.youtube.com/shorts/e1JL3T9sOlY If you’re new and need the basics on the pipeline and positioning, it’s a decent starting point. Just don’t confuse promotion with due diligence.
1 · Reply
Golden_Cross
Golden_Cross Feb. 11 at 2:26 PM
$BVAXF Great Looking Investment Opportunity Here! Think we could see a buyout in 2026! Rev's soon!
0 · Reply
wheresdannynow
wheresdannynow Feb. 9 at 9:42 PM
Cancer Network just highlighted $BVAXF $BIOV.CSE showing 40% ORR and 90% DCR using a combo with Merck & Co.’s Keytruda. Multi-year CRs. Durable immune response. Same DPX platform. Meanwhile BIOV trades at a ~$6M MC because liquidity is trash. This isn’t broken science. It’s a microcap flush. Asymmetry is obvious. #BIOV #BVAXF #Biotech #Oncology #Keytruda #MRK #SmallCaps #AsymmetricTrade https://www.cancernetwork.com/view/novel-vaccine-combo-shows-responses-in-recurrent-epithelial-ovarian-cancer
0 · Reply
Ventureville
Ventureville Feb. 9 at 5:07 PM
Biotech setup is getting ignored right before it turns. Crushed valuations. Tight funding. Pipelines still moving. That’s where sector rotations start. Risk is known. Upside is asymmetric. $BVAXF $SAVA $ALT $IBRX $XBI
0 · Reply
Golden_Cross
Golden_Cross Feb. 9 at 3:05 PM
$BVAXF Undervalued Biotech Play! https://www.youtube.com/watch?v=O0uEWvcgwRY
0 · Reply
Golden_Cross
Golden_Cross Feb. 6 at 3:07 PM
$BVAXF BioVaxys isn’t your average biotech. It’s a platform-first MACHINE backed by decades of science. https://www.instagram.com/reel/DS2WTkijoS9/
0 · Reply
wheresdannynow
wheresdannynow Feb. 5 at 6:40 PM
$BVAXF $BIOV.CSE SpayVac royalty revenue hits Q1 2026, that's literally weeks away and first commercial cash for BIOV. FDA/EPA done, regulatory submissions completed last Oct.
0 · Reply
Golden_Cross
Golden_Cross Feb. 5 at 4:33 PM
$BVAXF SpayVac Breakthrough: Single-dose immunocontraceptive slashed deer fertility to 11% (vs. 86% control) in peer-reviewed study—validated across 3 species. Regulatory submissions underway for horses/deer; royalties expected early 2026!
0 · Reply
Golden_Cross
Golden_Cross Feb. 4 at 7:31 PM
$BVAXF $BIOV.CSE BioVaxys Animal Health Strategic Partnerships ~ Revenues imminent here.
0 · Reply
resx18
resx18 Feb. 4 at 7:13 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow Feb. 4 at 5:55 PM
$BVAXF $BIOV.CSE Think we could see a buyout in 2026!
0 · Reply
Ventureville
Ventureville Feb. 4 at 3:48 PM
Solid team at $BVAXF $BIOV.CSE Passin brings the finance chops, Kovan the big pharma ops experience, and Dr. Berd the oncology research cred. No wonder they're pushing forward with promising DPX data lately.
0 · Reply
resx18
resx18 Feb. 4 at 3:38 PM
$BVAXF
0 · Reply